Kythera Biopharmaceuticals Inc  

(Public, NASDAQ:KYTH)   Watch this stock  
Find more results for KYTH
Pre-market: 74.94 -0.04 (-0.05%)
Oct 1, 8:25AM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 29.86 - 76.31
Open     -
Vol / Avg. 0.00/861,259.00
Mkt cap 1.97B
P/E     -
Div/yield     -
EPS -4.64
Shares 26.27M
Beta     -
Inst. own 91%
Nov 9, 2015
Q3 2015 KYTHERA Biopharmaceuticals Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -12900.69% -
Operating margin -12475.35% -
EBITD margin - -
Return on average assets -72.56% -97.98%
Return on average equity -93.97% -129.61%
Employees 106 -
CDP Score - -


27200 Agoura Rd Ste 200
AGOURA HILLS, CA 91301-5127
United States - Map
+1-818-5874500 (Phone)
+1-818-5874591 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


KYTHERA Biopharmaceuticals, Inc. (KYTHERA) is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of prescription products for the aesthetic medicine market. The Company's initial focus is on the facial aesthetics market. The Company's product candidate is ATX101, an injectable drug in late-stage clinical development for the treatment of submental fullness associated with submental fat, which commonly presents as an undesirable double chin. ATX101 is a formulation of a purified synthetic version of deoxycholic acid. The Company has completed Phase III clinical trials for ATX101 and has made regulatory filings outside the United States, in Canada, Switzerland and Australia.